President Trump's nominee to lead the Food and Drug Administration, Dr. Heidi Overton, faces a Senate confirmation hearing Thursday. A top White House domestic policy adviser and former chief policy adviser at a conservative think tank, Dr. Overton would be the first FDA commissioner to openly oppose mifepristone, calling the abortion pill "dangerous to women" and the overturning of Roe v. Wade "a huge victory for life." She co-authored a 2023 paper criticizing the FDA's expansion of abortion pill access via telemedicine.

Dr. Overton also worked to reduce childhood vaccine recommendations, standing beside President Trump last month as he signed an executive order on the issue. She drove a plan to stop federal recommendations for flu, RSV, and meningitis vaccines for children. Critics, including former FDA principal deputy commissioner Dr. Joshua Sharfstein, warn her nomination threatens the agency's integrity amid pressure from allies of tobacco, AI, cannabis, peptides, and kratom.

The hearing arrives as anti-abortion groups and conservative states push the FDA to restrict mifepristone, approved in 2000 and now the most common U.S. abortion method. Over 100 studies affirm its safety. The agency recently began a safety review and approved a new generic version last fall, setting up a critical test for Dr. Overton if confirmed.